Table 4.
Prevalence of HPV Genotypes in CIN3+ by TypeSeq and Linear Array
| HPV Type | TS+ | TS+ CIN3+ | Risk TS (%) | LA+ | LA+ CIN3+ | Risk LA (%) | TS−/LA− | TS−/LA+ | TS−/LA+ CIN3+ | Risk TS−/LA+a (%) | TS+/LA− | TS+/LA− CIN3+ | Risk TS+/LA−a (%) | TS+/LA+ | TS+/LA+ CIN3+ | Risk TS+/LA+ (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 | 1052 | 474 | 45.1 | 1067 | 476 | 44.6 | 1707 | 42 | 5 | 11.9 | 27 | 3 | 11.1 | 1025 | 471 | 46.0 |
| 18 | 280 | 75 | 26.8 | 268 | 74 | 27.6 | 2503 | 18 | 6 | 33.3 | 30 | 7 | 23.3 | 250 | 68 | 27.2 |
| 31 | 307 | 81 | 26.4 | 287 | 78 | 27.2 | 2482 | 12 | 2 | 16.7 | 32 | 5 | 15.6 | 275 | 76 | 27.6 |
| 33 | 138 | 39 | 28.3 | 121 | 35 | 28.9 | 2662 | 1 | 0 | 0.0 | 18 | 4 | 22.2 | 120 | 35 | 29.2 |
| 35 | 191 | 37 | 19.4 | 175 | 33 | 18.9 | 2602 | 8 | 2 | 25.0 | 24 | 6 | 25.0 | 167 | 31 | 18.6 |
| 39 | 230 | 27 | 11.7 | 238 | 33 | 13.9 | 2549 | 22 | 7 | 31.8 | 14 | 1 | 7.1 | 216 | 26 | 12.0 |
| 45 | 210 | 56 | 26.7 | 208 | 60 | 28.8 | 2572 | 19 | 9 | 47.4 | 21 | 5 | 23.8 | 189 | 51 | 27.0 |
| 51 | 321 | 43 | 13.4 | 314 | 40 | 12.7 | 2432 | 48 | 8 | 16.7 | 55 | 11 | 20.0 | 266 | 32 | 12.0 |
| 52 | 345 | 63 | 18.3 | 273 | 54 | 19.8 | 2436 | 23 | 7 | 30.3 | 95 | 16 | 16.8 | 250 | 47 | 18.8 |
| 56 | 224 | 28 | 12.5 | 204 | 21 | 10.3 | 2557 | 20 | 2 | 10.0 | 40 | 9 | 22.5 | 184 | 19 | 10.3 |
| 58 | 199 | 42 | 21.1 | 167 | 34 | 20.4 | 2598 | 4 | 0 | 0.0 | 36 | 8 | 22.2 | 163 | 34 | 20.9 |
| 59 | 219 | 38 | 17.4 | 216 | 39 | 18.1 | 2563 | 19 | 4 | 21.1 | 22 | 3 | 13.6 | 197 | 35 | 17.8 |
| 68 | 103 | 21 | 20.4 | 96 | 19 | 19.8 | 2692 | 6 | 0 | 0.0 | 13 | 2 | 15.4 | 90 | 19 | 21.1 |
Abbreviations: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; LA, Linear Array; TS, TypeSeq.
aThe difference in risk between TS−/LA and TS+/LA− was not significant for any of the types (P > .5).